Semaglutide: A Promising Ally Against Alzheimer’s?
In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.
Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.
Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.
Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.
Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.
According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.
“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”
Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.
For more information, please contact Patty Zamora at [email protected].
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
A Leon County judge has ordered Florida’s administrative courts to restart arbitration on more than 400 stalled Citizens Insurance cases, reigniting a legal showdown over whether the state’s insurer of last resort can force policyholders out of traditional courtrooms. The ruling directly conflicts with a separate Hillsborough County injunction that called Citizens’ arbitration system “likely unconstitutional,” setting up a rare judicial clash that could reshape how Floridians fight denied or underpaid property claims.
Inhabit has launched a powerful new suite of AI‑driven tools designed to modernize leasing, strengthen fraud prevention, and simplify compliance for property managers nationwide. From advanced leasing assistants and NYC‑specific regulatory AI to instant income verification and upcoming identity‑screening tech, these innovations aim to solve some of the industry’s toughest challenges. Real estate professionals—especially in multifamily—can expect faster operations, stronger safeguards, and a more efficient workflow as these technologies roll out.
A growing body of demographic research suggests that today’s housing shortage may give way to a future surplus as millions of Baby Boomer–owned homes return to the market over the next two decades. With affordability at historic lows and inventory still tight, this long‑term shift could eventually cool prices and transform the landscape for real estate professionals. The analysis draws parallels to aging populations abroad and highlights why understanding demographic cycles is becoming essential knowledge for agents, brokers, and mortgage professionals preparing for the next era of the housing market.
Griffin Funding has appointed John Jones as Senior Vice President of Growth and EOS Integrator, a move aimed at accelerating the lender’s push toward $3 billion in annual non‑QM loan volume by 2030. Jones, previously the company’s fractional integrator and COO, will lead expansion strategies, operational optimization, and leadership development as the lender strengthens its position in the increasingly competitive non‑QM market.
A new report shows Tampa outperforming the national real estate slowdown with a 6.5 percent annualized multifamily return, nearly 20 percent higher than the U.S. average. While many metros face oversupply or regulatory drag, Tampa’s balanced development pipeline, strong population growth, and investor confidence continue to fuel resilient performance heading into 2026.
A new Colliers outlook reveals that global capital is picking up momentum again, with investors shifting toward more active, hands‑on strategies. Data centers are surging, offices are rebounding, and value‑add plays like adaptive reuse are defining the next wave of opportunity. Regional markets—from the U.S. to APAC—are seeing renewed demand as fundraising spreads across continents and investors seek speed, control, and scale. This snapshot helps today’s real estate and finance professionals stay aligned with where global money is moving next.
